ArticleCancers2019
Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing.
Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Observational
- Genipin-Crosslinked, Silane-Anchored 3D Tumor-Stroma Microtissues for High-Content On-Chip Drug Testing.Advanced healthcare materials · 2026Article
- A Head and Neck Cancer Patient-Specific Microphysiological System for Predicting Response to Chemoradiation.bioRxiv : the preprint server for biology · 2026Article
- Head and neck cancer organoids: a panoramic perspective from basic construction to clinical translation.Stem cell research & therapy · 2025Review
- Three-dimensional in vitro models in head and neck cancer: current trends and applications.Medical oncology (Northwood, London, England) · 2025Review
- A bioengineered tumor matrix-based scaffold for the evaluation of melatonin efficacy on head and neck squamous cancer stem cells.Materials today. Bio · 2024Article
- Engineering models of head and neck and oral cancers on-a-chip.Biomicrofluidics · 2024Review
- In Vitro Models of Head and Neck Cancer: From Primitive to Most Advanced.Journal of personalized medicine · 2023Review
- The Three-Dimensional In Vitro Cell Culture Models in the Study of Oral Cancer Immune Microenvironment.Cancers · 2023Review
- Novel human lymph node-derived matrix supports the adhesion of metastatic oral carcinoma cells.BMC cancer · 2023Article
- Mapping the Potential of Microfluidics in Early Diagnosis and Personalized Treatment of Head and Neck Cancers.Cancers · 2023Review
- The effect of matrices on the gene expression profile of patient-derived head and neck carcinoma cells for in vitro therapy testing.Cancer cell international · 2023Article
- Amphipathic barbiturates as marine product mimics with cytolytic and immunogenic effects on head and neck squamous cell carcinoma cell lines.Frontiers in pharmacology · 2023Article
- Targeting PI3K/AKT/mTOR Signaling Pathway as a Radiosensitization in Head and Neck Squamous Cell Carcinomas.International journal of molecular sciences · 2022Review
- Evaluation of AMG510 Therapy onBioengineering (Basel, Switzerland) · 2022Article
- Review
- Review
- Comparative Analysis of Vascular Mimicry in Head and Neck Squamous Cell Carcinoma: In Vitro and In Vivo Approaches.Cancers · 2021Article
- High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma.Scientific reports · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
In vitro cancer drug testing carries a low predictive value. We developed the human leiomyoma-derived matrix "Myogel" to better mimic the human tumor microenvironment (TME). We hypothesized that Myogel could provide an appropriate microenvironment for cancer cells, thereby allowing more in vivo-relevant drug testing. We screened 19 anticancer compounds, targeting the epidermal growth factor receptor (EGFR), MEK, and PI3K/mTOR on 12 head and neck squamous cell carcinoma (HNSCC) cell lines cultured on plastic, mouse sarcoma-derived Matrigel (MSDM), and Myogel. We applied a high-throughput drug screening assay under five different culturing conditions: cells in two-dimensional (2D) plastic wells and on top or embedded in Matrigel or Myogel. We then compared the efficacy of the anticancer compounds to the response rates of 19 HNSCC monotherapy clinical trials. Cancer cells on top of Myogel responded less to EGFR and MEK inhibitors compared to cells cultured on plastic or Matrigel. However, we found a similar response to the PI3K/mTOR inhibitors under all culturing conditions. Cells grown on Myogel more closely resembled the response rates reported in EGFR-inhibitor monotherapy clinical trials. Our findings suggest that a human tumor matrix improves the predictability of in vitro anticancer drug testing compared to current 2D and MSDM methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.